Thermo Electron's biomedical sales rise 41% in 1994
This article was originally published in Clinica
Thermo Electron's total sales rose 27% in 1994 (see Clinica No 645, p 11) but growth has been different in the various segments, with one of the strongest performers its biomedical products division.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.